<?xml version="1.0" encoding="UTF-8"?>
<p>Under ordinary conditions, organ transplant recipients and those on immunosuppressants are at high risk of infection due in particular to the suppression of T cell response, making their susceptibility to SARS-CoV-2 and prognosis, if infected, unclear. On one hand, it has been postulated that reduction of systemic inflammation by immunosuppressants could improve outcome for COVID-19 patients as the severity of inflammatory response can be an indicator of prognosis [
 <xref rid="B50-pathogens-09-00430" ref-type="bibr">50</xref>]. However, it is also a case that immunosuppressed individuals tend to have a higher viral load, take longer to shed the virus, and may show more severe clinical symptoms with a poorer prognosis [
 <xref rid="B51-pathogens-09-00430" ref-type="bibr">51</xref>].
</p>
